CRISPR Therapeutics Company
CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. They have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from their scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing.
CRISPR Therapeutics’ vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. The company is headquartered in Basel, Switzerland and has operations in London, UK.
CRISPR Therapeutics’ vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. The company is headquartered in Basel, Switzerland and has operations in London, UK.
Investors
Technology:
Regenerative Medicine
Industry:
Gene therapy
Headquarters:
Cambridge, Massachusetts, United States
Founded Date:
7-5
Employees Number:
1-10
Funding Status:
IPO
Investors Number:
9
Total Funding:
$127M
Estimated Revenue:
$100M to $500M
Last Funding Type:
Series B
Register and Claim Ownership